ATE432077T1 - 5-arylpyrimidine als anti-krebs-mittel - Google Patents

5-arylpyrimidine als anti-krebs-mittel

Info

Publication number
ATE432077T1
ATE432077T1 AT04784529T AT04784529T ATE432077T1 AT E432077 T1 ATE432077 T1 AT E432077T1 AT 04784529 T AT04784529 T AT 04784529T AT 04784529 T AT04784529 T AT 04784529T AT E432077 T1 ATE432077 T1 AT E432077T1
Authority
AT
Austria
Prior art keywords
arylpyrimidine
cancer agent
cancer
agent
Prior art date
Application number
AT04784529T
Other languages
English (en)
Inventor
Nan Zhang
Semiramis Ayral-Kaloustian
Thai Nguyen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE432077T1 publication Critical patent/ATE432077T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04784529T 2003-09-24 2004-09-17 5-arylpyrimidine als anti-krebs-mittel ATE432077T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50548703P 2003-09-24 2003-09-24
PCT/US2004/030682 WO2005030216A1 (en) 2003-09-24 2004-09-17 5-arylpyrimidines as anticancer agents

Publications (1)

Publication Number Publication Date
ATE432077T1 true ATE432077T1 (de) 2009-06-15

Family

ID=34393022

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04784529T ATE432077T1 (de) 2003-09-24 2004-09-17 5-arylpyrimidine als anti-krebs-mittel

Country Status (24)

Country Link
US (1) US7524849B2 (de)
EP (1) EP1663241B1 (de)
JP (1) JP2007506746A (de)
KR (1) KR20060089215A (de)
CN (1) CN1871009A (de)
AR (1) AR045811A1 (de)
AT (1) ATE432077T1 (de)
AU (1) AU2004275733A1 (de)
BR (1) BRPI0414736A (de)
CA (1) CA2539235A1 (de)
CO (1) CO5690592A2 (de)
DE (1) DE602004021269D1 (de)
EC (1) ECSP066457A (de)
GT (1) GT200400188A (de)
IL (1) IL174305A0 (de)
MX (1) MXPA06003207A (de)
NO (1) NO20061319L (de)
PA (1) PA8613201A1 (de)
PE (1) PE20050470A1 (de)
RU (1) RU2006107578A (de)
SA (1) SA04250303A (de)
TW (1) TW200512198A (de)
WO (1) WO2005030216A1 (de)
ZA (1) ZA200602386B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
CN101193884A (zh) 2005-06-13 2008-06-04 惠氏公司 微管蛋白抑制剂和其制备方法
CA2610416A1 (en) * 2005-06-13 2006-12-28 Wyeth Tubulin inhibitor and process for its preparation
AR060140A1 (es) * 2006-03-27 2008-05-28 Basf Ag 5-heteroaril-4-aminopirimidinas sustituidas
CL2007002231A1 (es) * 2006-08-02 2008-04-11 Basf Ag Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico.
WO2008084081A2 (en) * 2007-01-11 2008-07-17 Basf Se 2-substituted 5-phenylpyrimidines for the treatment of proliferative disorders
WO2009007187A1 (de) * 2007-07-09 2009-01-15 Basf Se Substituierte 5-hetarylpyrimidine
PL2699553T3 (pl) 2011-04-22 2024-03-25 Signal Pharmaceuticals, Llc Podstawione diaminokarboksyamido- i diaminokarbonitrylo-pirymidyny, ich kompozycje i sposoby leczenia nimi
EP2903436B1 (de) * 2012-09-19 2019-07-17 The Trustees Of The University Of Pennsylvania Heterocyclische verbindungen und deren verwendung zur behandlung neurodegenerativer tauopathien
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
MX2017007883A (es) 2014-12-16 2017-09-05 Signal Pharm Llc Formulaciones de 2-(ter-butilamino)-4-((1r,3r,4r)-3-hdroxi-4-metil ciclohexilamino)-pirimidina-5-carboxamida.
EP3233808B1 (de) 2014-12-16 2021-07-14 Signal Pharmaceuticals, LLC Medizinische verwendungen, die verfahren zur messung der hemmung der c-jun-n-terminalen kinase in der haut beinhalten
US20180022710A1 (en) 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
ES2819374T3 (es) 2015-07-24 2021-04-15 Celgene Corp Métodos de síntesis del hidrocloruro de (1R,2R,5R)-5-amino-2-metilciclohexanol e intermedios útiles en los mismos
EP3758696A4 (de) 2018-03-02 2021-12-08 The Trustees of the University of Pennsylvania [1,2,4]triazolo[1,5-a]pyrimidin-verbindungen und verwendung davon zur stabilisierung von mikrotubuli
EP4052759A4 (de) * 2019-11-01 2023-12-20 Unimatec Co., Ltd. Fluorhaltige pyrimidinverbindung und verfahren zu ihrer herstellung
TW202132285A (zh) * 2019-11-13 2021-09-01 美商愛彼特生物製藥股份有限公司 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US147744A (en) * 1874-02-24 Improvement in locomotive-furnaces
US88096A (en) * 1869-03-23 t h a y e r
US69242A (en) * 1867-09-24 Calvin pepper
US116429A (en) * 1871-06-27 Improvement in dial-telegraph apparatus
US61889A (en) * 1867-02-05 Improvement in animal teaps
GB9700664D0 (en) 1997-01-14 1997-03-05 British Tech Group Anti-cancer agents
US6117876A (en) * 1997-04-14 2000-09-12 American Cyanamid Company Fungicidal trifluorophenyl-triazolopyrimidines
WO1999055668A1 (fr) 1998-04-27 1999-11-04 Kumiai Chemical Industry Co., Ltd. Derives du 3-arylphenyl-sulfure, insecticides et acaricides
US6156925A (en) * 1998-09-25 2000-12-05 American Cyanamid Company Process for the preparation of halogenated phenylmaloates
US5986135A (en) * 1998-09-25 1999-11-16 American Cyanamid Company Fungicidal trifluoromethylalkylamino-triazolopyrimidines
EA005927B1 (ru) * 2000-06-13 2005-08-25 Басф Акциенгезельшафт Фунгицидные 5-фенил-замещенные 2-(цианоамино)пиримидины
US6670362B2 (en) * 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
IL157723A0 (en) * 2001-03-15 2004-03-28 Basf Ag 5-phenylpyrimidine, methods and intermediate products for the production thereof and use of the same for controlling pathogenic fungi
ES2242839T3 (es) * 2001-04-20 2005-11-16 Ciba Specialty Chemicals Holding Inc. 4-amino-2- (piridin-2-il)pirimidina como sustancias activas microbicidas.
EP1448532A1 (de) 2001-11-19 2004-08-25 BASF Aktiengesellschaft 5-phenylpyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
DE50311420D1 (de) 2002-02-21 2009-05-28 Basf Se 2-(2-pyridyl)-5-phenyl-6-aminopyrimidine, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen
ATE366045T1 (de) 2002-03-15 2007-07-15 Ciba Sc Holding Ag Verwendung von 4-aminopyrimidinen zur antimikrobiellen behandlung von oberflächen
ES2375111T3 (es) 2002-11-21 2012-02-24 Novartis Ag Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-quinasa y su uso en el tratamiento de c�?ncer.

Also Published As

Publication number Publication date
ECSP066457A (es) 2006-09-18
TW200512198A (en) 2005-04-01
CA2539235A1 (en) 2005-04-07
CN1871009A (zh) 2006-11-29
SA04250303A (ar) 2005-12-03
BRPI0414736A (pt) 2006-11-21
EP1663241A1 (de) 2006-06-07
DE602004021269D1 (de) 2009-07-09
AU2004275733A1 (en) 2005-04-07
MXPA06003207A (es) 2006-06-23
IL174305A0 (en) 2008-02-09
NO20061319L (no) 2006-04-20
US20050075357A1 (en) 2005-04-07
US7524849B2 (en) 2009-04-28
KR20060089215A (ko) 2006-08-08
WO2005030216A1 (en) 2005-04-07
ZA200602386B (en) 2009-03-25
RU2006107578A (ru) 2007-10-27
PA8613201A1 (es) 2005-11-25
PE20050470A1 (es) 2005-10-03
CO5690592A2 (es) 2006-10-31
EP1663241B1 (de) 2009-05-27
JP2007506746A (ja) 2007-03-22
AR045811A1 (es) 2005-11-16
GT200400188A (es) 2005-05-02

Similar Documents

Publication Publication Date Title
NL301059I2 (nl) Darvadstrocel
DE602004015724D1 (de) Diazepinoindolderivate als kinaseinhibitoren
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE60330694D1 (de) Pyrimidopyrimidone als kinaseinhibitoren
DE602004018654D1 (de) Se
ATE354631T1 (de) Nuancierungsmittel
ATE363383T1 (de) Schlingenware
DE602004004495D1 (de) Folientastatur
DE602004028376D1 (de) Bewegliche einheit
FR2862654B1 (fr) Composition amylacee filmogene
AT502792A5 (de) Düsenanpressvorrichtung
ATE432077T1 (de) 5-arylpyrimidine als anti-krebs-mittel
DE602005015844D1 (de) Kompaktes stellglied
ATE372323T1 (de) Als antivirale mittel geeignete 4- carboxypyrazolderivate
DE602004004295D1 (de) 6-ä(substituiertes)phenylütriazolopyrimidine als antikrebsmittel
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten
ATA662003A (de) Trink-mundstück
ATE446959T1 (de) Chromenonindole
DE602004001250D1 (de) Tastatur
DE60328233D1 (de) Sulfamatbenzothiophenderivate als steroidsulfataseinhibitoren
ITMI20031989A1 (it) Tastiera per non vedenti
ATE406350T1 (de) Prolinylarylacetamide
FR2861343B1 (fr) Appui-tete rabattable
DE502004006442D1 (de) Bauelement

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties